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Background
We have previously investigated the frequency of gene
mutations in RET and HRAS affecting medullary thyroid
carcinomas (MTCs) and gene mutations in BRAF, HRAS,
KRAS, and NRAS affecting non-medullary thyroid carci-
nomas (non-MTCs). Non-MTCs include follicular TCs
(FTCs), anaplastic TCs (ATCs), and papillary TCs (PTCs)
and its histological variants. In this study we surveyed the
frequency of metastasis to the brain or bone in our case
series of MTCs and non-MTCs.
Materials and methods
We surveyed histopathological reports from two main
hospitals in the Western region of Saudi Arabia for the
presence of brain and/or bone metastasis in a case series
of malignant TCs comprising 13 MTCs and 238 non-
MTCs.
Results
Our survey identified a small number of malignant TCs
affected with bone and/or brain metastasis. Out of 115
PTCs, two cases were reported to have a metastasis to
the bone and one case had a concurrent metastasis to the
brain and to the skull bone. One case with a metastasis
to the bone revealed in the mutational screening an
uncommon K601E mutation in the BRAF gene whereas a
rare insertion in BRAF codon 599 (insT599T) was identi-
fied in the case with the metastases to the brain and skull
bone. This latter mutation was confined to the tumor.
Out of 42 FVPTCs (follicular variants of PTCs), two
cases were reported to have a metastasis to the bone.
One of the FVPTCs displayed a HRAS Q61K mutation.
In addition, one patient presenting with a micro PTC
(tumor size ≤1 cm) had a brain metastasis originating
from a breast carcinoma.
Conclusions
Our survey reveals that especially, metastases to the
brain are infrequent events in malignant TCs which is
in concordance with other surveys [1]. The association
of rare BRAF mutations with brain and bone metastasis
from TC requires further investigations.
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